That finding, from researchers at the University of Texas Southwestern Medical Center at Dallas, appears in the April 15 issue of the American Journal of Cardiology.
Researchers combined low-dose simvastatin, which targets low-density lipoprotein (LDL) cholesterol (bad cholesterol), with the drug fenofibrate, which increases high-density lipoprotein (HDL) cholesterol (good cholesterol).
The study included 20 people with combined hyperlipidemia, a condition characterized by high triglycerides, high LDL cholesterol and low HDL cholesterol.
High LDL is a risk factor for coronary heart disease, and low HDL and high triglycerides also increase the risk.
When they were put on the simvastatin/fenofibrate combination, the study volunteers had a 52 percent reduction in triglycerides, a 23 percent increase in HDL and a 28 percent decrease n LDL.
"This study provides reasonable evidence that a low dose of statin plus fenofibrate is a relatively safe and effective drug combination for treating LDL and several emerging risk factors for coronary heart disease," principal investigator Dr. Gloria Vega says in a news release.
Here's where you can learn more about coronary heart disease.